The trial established that the drug had significantly improved the progression-free survival (PFS) in ovarian cancer patients with germline BRCA-mutations (gBRCA) whose disease had relapsed, and had also
Keytruda (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, has been approved to treat adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or who have relapsed after
A team at the university used a technique, called a kiss of death, which forces molecules to bind to proteins such as Ras and Myc. Led by Professor Alessio Ciulli in Dundee’s School
Kisqali, which is a selective cyclin-dependent kinase inhibitor, has been approved as initial endocrine-based therapy to treat postmenopausal women with hormone receptor positive and human epidermal growth factor
Synairgen is collaboraing with Australian firm Pharmaxis on the program which will target scar tissue that inhibits breathing in sufferers of idiopathic pulmonary fibrosis (IPF), a lethal lung condition. If
Servier, which took the responsibility of the CALM Phase 1 study, purchased exclusive rights of UCART19 from Cellectis in 2015. Last August, the CALM study was started in
Plans include the development of a new R&D center and advanced manufacturing and packaging facility that will serve as the US headquarters for Apotex and the US offices for Apobiologix, the company’s biosimilar
The JV, BeiGene Biologics, will build the facility in Guangzhou, Guangdong Province. The project is expected to break ground this year. BeiGene Biologics will use some of the funding to
Ledaga is formulated as a topical, once-daily and colorless gel. MF-CTCL is a rare and potentially life-threatening immune system cancer that forms on the skin. It is the common
Waking up at least two times per night to urinate is known as nocturnal polyuria, overproduction of urine during the night. Noctiva, which is a vasopressin analog, is
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.